What We're Reading: Page 158
Industry reads hand-picked by our editors
Mar 18, 2021
-
Science
‘It’s a very special picture.’ Why vaccine safety experts put the brakes on AstraZeneca’s COVID-19 vaccine
-
Fierce Biotech
GSK licenses early-stage cancer, CNS programs to Boston Pharma—with repurchase option
-
Science Translational Medicine
The Problem with COVID-19 Clinical Trials
-
Endpoints News
Lilly’s Covid-19 drug bamlanivimab is no longer distributed in 3 states because of a variant, Woodcock says
Mar 17, 2021
-
The New York Times
Why Europe Suspending AstraZeneca Vaccines May Be Political
-
FiercePharma
In another Merck executive switch, chief marketing officer Nally exits and CCO Clyburn steps up
-
The Wall Street Journal
Startup Behind AstraZeneca Covid-19 Vaccine Raises $168 Million in Step Toward IPO
-
Reuters
Pfizer to halt biosimilar output in China, sell assets to WuXi Biologics
Mar 16, 2021
-
The New York Times
Moderna Begins Testing Its Covid Vaccine in Babies and Young Children
-
Reuters
AbbVie in talks to sell $5 billion women's drugs portfolio
-
The Wall Street Journal
OxyContin Owner Increases Settlement Offer to $4.28 Billion
-
Evaluate Vantage
No knockout blow from Rubius
Mar 15, 2021
-
Nature Biotechnology
The next 25 years
-
Reuters
Money, talent flowing into mRNA sector after COVID-19 success
-
Financial Times
Insitro raises $400M for machine learning drug discovery push
-
Boston Business Journal
Indian biopharma spins out Cambridge oncology startup Bicara
Mar 12, 2021
-
The New York Times
The U.S. Is Sitting on Tens of Millions of Vaccine Doses the World Needs
-
Evaluate Vantage
After US approval Aveo faces a monumental task
-
STAT
Reining in drug patents isn't a silver bullet against high drug prices
-
FierceBiotech
Lilly rejoins KRAS race with swipe at Amgen and Mirati, plans 2021 clinical trial
Mar 11, 2021
-
Reuters
Insider alleges Eli Lilly blocked her efforts to sound alarms about U.S. drug factory
-
Bloomberg
J&J Vaccine Rollout Slowed by Shifting State Strategies
-
Evaluate Vantage
Gilead challenges Viiv in heavily treated HIV
-
Endpoints News
Aveo Oncology gets the long-awaited greenlight to market tivozanib — 9 years after filing its first NDA
Mar 10, 2021
-
Bloomberg
Biden Duo's Nudge Eased Merck-J&J Logjam to Speed Vaccine Output
-
NPR
In The '24th Mile' Of A Marathon, Fauci And Collins Reflect On Their Pandemic Year
-
The Sunday Times
GlaxoSmithKline doubles cash paid to doctors for promoting its drugs
-
In the Pipeline
Drug Approvals Over the Last Ten Years
Previous
